Lung Cancer Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Lung Cancer Market: By Diagnostics Method (Chest X-ray, Cystoscopy, 18F-FDG PET scanning, Bronchoscopy, Endobronchial Biopsy Scan (EBUS), Biopsy), By Type (Small Cell Lung Cancer, Non-small Cell lung Cancer), By Treatment (Surgery, Chemotherapy, Immunotherapy, Targeted Therapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

1. Executive Summary
2. Global Lung Cancer Market Introduction
2.1. Global Lung Cancer Market – Taxonomy
2.2. Global Lung Cancer Market –Definitions
2.2.1. By Diagnostics Method
2.2.2. By Type
2.2.3. By Treatment
2.2.4. By Distribution Channel
2.2.5. By Region
3.Global Lung Cancer Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Lung Cancer Market Dynamic Factors – Impact Analysis
3.6. Impact of COVID-19 on The Market
3.7. Three Forecast Scenarios – Pessimistic, Conservative, and Opportunistic
3.8. Mapping Market Players’ Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations, and Mergers
4.Global Lung Cancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Lung Cancer Market Forecast, By Diagnostics Method, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1. Chest X-ray
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. CT scan
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. 18F-FDG PET scanning
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Bronchoscopy
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Endobronchial Biopsy Scan (EBUS)
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Biopsy
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Lung Cancer Market Forecast, By Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1. Small Cell Lung Cancer
6.1.1. Small cell carcinoma (oat cell cancer).
6.1.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.1.3. Market Opportunity Analysis
6.1.2. Combined small cell carcinoma.
6.1.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.2.3. Market Opportunity Analysis
6.2. Non-small Cell lung Cancer
6.2.1. Squamous cell carcinoma
6.2.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.1.3. Market Opportunity Analysis
6.2.2. Large cell carcinoma
6.2.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.2.3. Market Opportunity Analysis
6.2.3. Adenocarcinoma
6.2.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3.3. Market Opportunity Analysis
6.2.4. Others
6.2.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.4.3. Market Opportunity Analysis
7. Market Opportunity Analysis Global Lung Cancer Market Forecast, By Treatment, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1. Surgery
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Chemotherapy
7.2.1. Vinca Alkaloids
7.2.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.1.3. Market Opportunity Analysis
7.2.2. Antimetabolites
7.2.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.2.3. Market Opportunity Analysis
7.2.3. Taxanes
7.2.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3.3. Market Opportunity Analysis
7.2.4. Podophyllotoxin Derivatives
7.2.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.4.3. Market Opportunity Analysis
7.2.5. Platinum-Containing Compounds
7.2.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.5.3. Market Opportunity Analysis
7.2.6. Antifolate Antineoplastic Agents
7.2.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.6.3. Market Opportunity Analysis
7.3. Immunotherapy
7.3.1. PD-1/PD-L1 inhibitors
7.3.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.1.3. Market Opportunity Analysis
7.3.2. CTLA-4 inhibitor
7.3.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.2.3. Market Opportunity Analysis
7.3.3. Others
7.3.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3.3. Market Opportunity Analysis
7.4. Targeted Therapy
7.4.1. Angiogenesis Inhibitors
7.4.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.1.3. Market Opportunity Analysis
7.4.2. KRAS inhibitor
7.4.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.2.3. Market Opportunity Analysis
7.4.3. KRAS inhibitor
7.4.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3.3. Market Opportunity Analysis
7.4.4. EGFR inhibitors
7.4.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.4.3. Market Opportunity Analysis
7.4.5. ALK inhibitors
7.4.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.5.3. Market Opportunity Analysis
7.5. Radiation Therapy
7.5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.1.3. Market Opportunity Analysis
8. Market Opportunity Analysis Global Lung Cancer Market Forecast, By Distribution Channel, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1. Hospital Pharmacy
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacy
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacy
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9.Global Lung Cancer Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1. North America
9.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Lung Cancer Market – Opportunity Analysis Index, By By Diagnostics Method, By Type, By Treatment, By Distribution Channel, and Region, 2022 – 2028
10.  North America Lung Cancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
10.1. By Diagnostics Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Chest X-ray
10.1.2. Cytoscopy
10.1.3. 18F-FDG PET scanning
10.1.4. Bronchoscopy
10.1.5. Endobronchial Biopsy Scan (EBUS)
10.1.6. Biopsy
10.2. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Non Non-small Cell lung Cancer
10.2.1.1. Small cell carcinoma (oat cell cancer).
10.2.1.2. Combined small cell carcinoma.
10.2.2. Non-small Cell lung Cancer
10.2.2.1. Squamous cell carcinoma
10.2.2.2. Large cell carcinoma
10.2.2.3. Adenocarcinoma
10.2.2.4. Others
10.3. By Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Surgery
10.3.2. Chemotherapy
10.3.2.1. Platinum Containing Compound
10.3.2.2. Taxanes
10.3.2.3. Antimetabolites
10.3.2.4. vinca alkaloids
10.3.2.5. podophyllotoxin derivatives
10.3.2.6. antifolate antineoplastic agents
10.3.3. Immunotherapy
10.3.3.1. PD-1/PD-L1 inhibitors
10.3.3.2. CTLA-4 inhibitor
10.3.3.3. Others
10.3.4. Targeted Therapy
10.3.4.1. angiogenesis inhibitors
10.3.4.2. KRAS inhibitor
10.3.4.3. EGFR inhibitors
10.3.4.4. ALK inhibitors
10.3.4.5. Others
10.3.5. Radiation Therapy
10.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacy
10.4.2. Retail Pharmacy
10.4.3. Online Pharmacy
10.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Lung Cancer Market – Opportunity Analysis Index, By By Diagnostics Method, By Type, By Treatment, By Distribution Channel and Country, 2022 – 2028
10.7. North America Lung Cancer Market Dynamics – Trends
11.  Europe Lung Cancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
11.1. By Diagnostics Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Chest X-ray
11.1.2. Cytoscopy
11.1.3. 18F-FDG PET scanning
11.1.4. Bronchoscopy
11.1.5. Endobronchial Biopsy Scan (EBUS)
11.1.6. Biopsy
11.2. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Non Non-small Cell lung Cancer
11.2.1.1. Small cell carcinoma (oat cell cancer).
11.2.1.2. Combined small cell carcinoma.
11.2.2. Non-small Cell lung Cancer
11.2.2.1. Squamous cell carcinoma
11.2.2.2. Large cell carcinoma
11.2.2.3. Adenocarcinoma
11.2.2.4. Others
11.3. By Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Surgery
11.3.2. Chemotherapy
11.3.2.1. Platinum Containing Compound
11.3.2.2. Taxanes
11.3.2.3. Antimetabolites
11.3.2.4. vinca alkaloids
11.3.2.5. podophyllotoxin derivatives
11.3.2.6. antifolate antineoplastic agents
11.3.3. Immunotherapy
11.3.3.1. PD-1/PD-L1 inhibitors
11.3.3.2. CTLA-4 inhibitor
11.3.3.3. Others
11.3.4. Targeted Therapy
11.3.4.1. angiogenesis inhibitors
11.3.4.2. KRAS inhibitor
11.3.4.3. EGFR inhibitors
11.3.4.4. ALK inhibitors
11.3.4.5. Others
11.3.5. Radiation Therapy
11.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacy
11.4.2. Retail Pharmacy
11.4.3. Online Pharmacy
11.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Europe Lung Cancer Market – Opportunity Analysis Index, By Diagnostics Method, By Type, By Treatment, By Distribution Channel and Country, 2022 – 2028
11.7. Europe Lung Cancer Market Dynamics – Trends
12.  Asia-Pacific Lung Cancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
12.1. By Diagnostics Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Chest X-ray
12.1.2. Cytoscopy
12.1.3. 18F-FDG PET scanning
12.1.4. Bronchoscopy
12.1.5. Endobronchial Biopsy Scan (EBUS)
12.1.6. Biopsy
12.2. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Non Non-small Cell lung Cancer
12.2.1.1. Small cell carcinoma (oat cell cancer).
12.2.1.2. Combined small cell carcinoma.
12.2.2. Non-small Cell lung Cancer
12.2.2.1. Squamous cell carcinoma
12.2.2.2. Large cell carcinoma
12.2.2.3. Adenocarcinoma
12.2.2.4. Others
12.3. By Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Surgery
12.3.2. Chemotherapy
12.3.2.1. Platinum Containing Compound
12.3.2.2. Taxanes
12.3.2.3. Antimetabolites
12.3.2.4. vinca alkaloids
12.3.2.5. podophyllotoxin derivatives
12.3.2.6. antifolate antineoplastic agents
12.3.3. Immunotherapy
12.3.3.1. PD-1/PD-L1 inhibitors
12.3.3.2. CTLA-4 inhibitor
12.3.3.3. Others
12.3.4. Targeted Therapy
12.3.4.1. angiogenesis inhibitors
12.3.4.2. KRAS inhibitor
12.3.4.3. EGFR inhibitors
12.3.4.4. ALK inhibitors
12.3.4.5. Others
12.3.5. Radiation Therapy
12.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacy
12.4.2. Retail Pharmacy
12.4.3. Online Pharmacy
12.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Rest of Asia-Pacific
12.6. Asia-Pacific Lung Cancer Market – Opportunity Analysis Index, By By Diagnostics Method, By Type, By Treatment, By Distribution Channel  and Country, 2022 – 2028
12.7. Asia-Pacific Lung Cancer Market Dynamics – Trends
13.  Latin America Lung Cancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
13.1. By Diagnostics Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.1.1. Chest X-ray
13.1.2. Cytoscopy
13.1.3. 18F-FDG PET scanning
13.1.4. Bronchoscopy
13.1.5. Endobronchial Biopsy Scan (EBUS)
13.1.6. Biopsy
13.2. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Non Non-small Cell lung Cancer
13.2.1.1. Small cell carcinoma (oat cell cancer).
13.2.1.2. Combined small cell carcinoma.
13.2.2. Non-small Cell lung Cancer
13.2.2.1. Squamous cell carcinoma
13.2.2.2. Large cell carcinoma
13.2.2.3. Adenocarcinoma
13.2.2.4. Others
13.3. By Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Surgery
13.3.2. Chemotherapy
13.3.2.1. Platinum Containing Compound
13.3.2.2. Taxanes
13.3.2.3. Antimetabolites
13.3.2.4. vinca alkaloids
13.3.2.5. podophyllotoxin derivatives
13.3.2.6. antifolate antineoplastic agents
13.3.3. Immunotherapy
13.3.3.1. PD-1/PD-L1 inhibitors
13.3.3.2. CTLA-4 inhibitor
13.3.3.3. Others
13.3.4. Targeted Therapy
13.3.4.1. angiogenesis inhibitors
13.3.4.2. KRAS inhibitor
13.3.4.3. EGFR inhibitors
13.3.4.4. ALK inhibitors
13.3.4.5. Others
13.3.5. Radiation Therapy
13.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacy
13.4.2. Retail Pharmacy
13.4.3. Online Pharmacy
13.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Argentina
13.5.3. Rest of Latin America
13.6. Latin America Lung Cancer Market – Opportunity Analysis Index, By By Diagnostics Method, By Type, By Treatment, By Distribution Channel and Country, 2022 – 2028
13.7. Latin America Lung Cancer Market Dynamics – Trends
14.  Middle East and Africa Lung Cancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
14.1. By Diagnostics Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.1.1. Chest X-ray
14.1.2. Cytoscopy
14.1.3. 18F-FDG PET scanning
14.1.4. Bronchoscopy
14.1.5. Endobronchial Biopsy Scan (EBUS)
14.1.6. Biopsy
14.2. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Non Non-small Cell lung Cancer
14.2.1.1. Small cell carcinoma (oat cell cancer).
14.2.1.2. Combined small cell carcinoma.
14.2.2. Non-small Cell lung Cancer
14.2.2.1. Squamous cell carcinoma
14.2.2.2. Large cell carcinoma
14.2.2.3. Adenocarcinoma
14.2.2.4. Others
14.3. By Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Surgery
14.3.2. Chemotherapy
14.3.2.1. Platinum Containing Compound
14.3.2.2. Taxanes
14.3.2.3. Antimetabolites
14.3.2.4. vinca alkaloids
14.3.2.5. podophyllotoxin derivatives
14.3.2.6. antifolate antineoplastic agents
14.3.3. Immunotherapy
14.3.3.1. PD-1/PD-L1 inhibitors
14.3.3.2. CTLA-4 inhibitor
14.3.3.3. Others
14.3.4. Targeted Therapy
14.3.4.1. angiogenesis inhibitors
14.3.4.2. KRAS inhibitor
14.3.4.3. EGFR inhibitors
14.3.4.4. ALK inhibitors
14.3.4.5. Others
14.3.5. Radiation Therapy
14.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacy
14.4.2. Retail Pharmacy
14.4.3. Online Pharmacy
14.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Saudi Arabia
14.5.2. GCC Countries
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Lung Cancer Market – Opportunity Analysis Index, By By Diagnostics Method, By Type, By Treatment, By Distribution Channel  and Country, 2022 – 2028
14.7. MEA Lung Cancer Market Dynamics – Trends
15.  Competition Landscape 
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, By Diagnostics Method Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Genentech (F. Hoffmann-La Roche Ltd)
15.2.2. Eli Lilly and Company
15.2.3. Celgene Corporation
15.2.4. AstraZeneca
15.2.5. Pfizer Inc.
15.2.6. Sanofi
15.2.7. Novartis AG
15.2.8. Astellas
15.2.9. Bristol Myers Squibb
15.2.10. Boehringer Ingelheim Pharmaceuticals, Inc.
15.2.11. Millennium Pharmaceuticals, Inc.
15.2.12. Merck Sharp & Dohme Corp.
16.  Research Methodology
17.  Key Assumptions and Acronyms

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Company Profile

 

  • Genentech (F. Hoffmann-La Roche Ltd)
  •  Eli Lilly and Company
  • Celgene Corporation
  • AstraZeneca
  • Pfizer Inc.
  • Sanofi
  • Novartis AG
  • Astellas
  • Bristol Myers Squibb
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Merck Sharp & Dohme Corp.

Description

1. Executive Summary
2. Global Lung Cancer Market Introduction
2.1. Global Lung Cancer Market – Taxonomy
2.2. Global Lung Cancer Market –Definitions
2.2.1. By Diagnostics Method
2.2.2. By Type
2.2.3. By Treatment
2.2.4. By Distribution Channel
2.2.5. By Region
3.Global Lung Cancer Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Lung Cancer Market Dynamic Factors – Impact Analysis
3.6. Impact of COVID-19 on The Market
3.7. Three Forecast Scenarios – Pessimistic, Conservative, and Opportunistic
3.8. Mapping Market Players’ Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations, and Mergers
4.Global Lung Cancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Lung Cancer Market Forecast, By Diagnostics Method, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1. Chest X-ray
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. CT scan
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. 18F-FDG PET scanning
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Bronchoscopy
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Endobronchial Biopsy Scan (EBUS)
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Biopsy
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Lung Cancer Market Forecast, By Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1. Small Cell Lung Cancer
6.1.1. Small cell carcinoma (oat cell cancer).
6.1.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.1.3. Market Opportunity Analysis
6.1.2. Combined small cell carcinoma.
6.1.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.2.3. Market Opportunity Analysis
6.2. Non-small Cell lung Cancer
6.2.1. Squamous cell carcinoma
6.2.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.1.3. Market Opportunity Analysis
6.2.2. Large cell carcinoma
6.2.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.2.3. Market Opportunity Analysis
6.2.3. Adenocarcinoma
6.2.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3.3. Market Opportunity Analysis
6.2.4. Others
6.2.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.4.3. Market Opportunity Analysis
7. Market Opportunity Analysis Global Lung Cancer Market Forecast, By Treatment, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1. Surgery
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Chemotherapy
7.2.1. Vinca Alkaloids
7.2.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.1.3. Market Opportunity Analysis
7.2.2. Antimetabolites
7.2.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.2.3. Market Opportunity Analysis
7.2.3. Taxanes
7.2.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3.3. Market Opportunity Analysis
7.2.4. Podophyllotoxin Derivatives
7.2.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.4.3. Market Opportunity Analysis
7.2.5. Platinum-Containing Compounds
7.2.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.5.3. Market Opportunity Analysis
7.2.6. Antifolate Antineoplastic Agents
7.2.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.6.3. Market Opportunity Analysis
7.3. Immunotherapy
7.3.1. PD-1/PD-L1 inhibitors
7.3.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.1.3. Market Opportunity Analysis
7.3.2. CTLA-4 inhibitor
7.3.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.2.3. Market Opportunity Analysis
7.3.3. Others
7.3.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3.3. Market Opportunity Analysis
7.4. Targeted Therapy
7.4.1. Angiogenesis Inhibitors
7.4.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.1.3. Market Opportunity Analysis
7.4.2. KRAS inhibitor
7.4.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.2.3. Market Opportunity Analysis
7.4.3. KRAS inhibitor
7.4.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3.3. Market Opportunity Analysis
7.4.4. EGFR inhibitors
7.4.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.4.3. Market Opportunity Analysis
7.4.5. ALK inhibitors
7.4.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.5.3. Market Opportunity Analysis
7.5. Radiation Therapy
7.5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.1.3. Market Opportunity Analysis
8. Market Opportunity Analysis Global Lung Cancer Market Forecast, By Distribution Channel, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1. Hospital Pharmacy
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacy
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacy
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9.Global Lung Cancer Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1. North America
9.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Lung Cancer Market – Opportunity Analysis Index, By By Diagnostics Method, By Type, By Treatment, By Distribution Channel, and Region, 2022 – 2028
10.  North America Lung Cancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
10.1. By Diagnostics Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Chest X-ray
10.1.2. Cytoscopy
10.1.3. 18F-FDG PET scanning
10.1.4. Bronchoscopy
10.1.5. Endobronchial Biopsy Scan (EBUS)
10.1.6. Biopsy
10.2. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Non Non-small Cell lung Cancer
10.2.1.1. Small cell carcinoma (oat cell cancer).
10.2.1.2. Combined small cell carcinoma.
10.2.2. Non-small Cell lung Cancer
10.2.2.1. Squamous cell carcinoma
10.2.2.2. Large cell carcinoma
10.2.2.3. Adenocarcinoma
10.2.2.4. Others
10.3. By Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Surgery
10.3.2. Chemotherapy
10.3.2.1. Platinum Containing Compound
10.3.2.2. Taxanes
10.3.2.3. Antimetabolites
10.3.2.4. vinca alkaloids
10.3.2.5. podophyllotoxin derivatives
10.3.2.6. antifolate antineoplastic agents
10.3.3. Immunotherapy
10.3.3.1. PD-1/PD-L1 inhibitors
10.3.3.2. CTLA-4 inhibitor
10.3.3.3. Others
10.3.4. Targeted Therapy
10.3.4.1. angiogenesis inhibitors
10.3.4.2. KRAS inhibitor
10.3.4.3. EGFR inhibitors
10.3.4.4. ALK inhibitors
10.3.4.5. Others
10.3.5. Radiation Therapy
10.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacy
10.4.2. Retail Pharmacy
10.4.3. Online Pharmacy
10.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Lung Cancer Market – Opportunity Analysis Index, By By Diagnostics Method, By Type, By Treatment, By Distribution Channel and Country, 2022 – 2028
10.7. North America Lung Cancer Market Dynamics – Trends
11.  Europe Lung Cancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
11.1. By Diagnostics Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Chest X-ray
11.1.2. Cytoscopy
11.1.3. 18F-FDG PET scanning
11.1.4. Bronchoscopy
11.1.5. Endobronchial Biopsy Scan (EBUS)
11.1.6. Biopsy
11.2. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Non Non-small Cell lung Cancer
11.2.1.1. Small cell carcinoma (oat cell cancer).
11.2.1.2. Combined small cell carcinoma.
11.2.2. Non-small Cell lung Cancer
11.2.2.1. Squamous cell carcinoma
11.2.2.2. Large cell carcinoma
11.2.2.3. Adenocarcinoma
11.2.2.4. Others
11.3. By Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Surgery
11.3.2. Chemotherapy
11.3.2.1. Platinum Containing Compound
11.3.2.2. Taxanes
11.3.2.3. Antimetabolites
11.3.2.4. vinca alkaloids
11.3.2.5. podophyllotoxin derivatives
11.3.2.6. antifolate antineoplastic agents
11.3.3. Immunotherapy
11.3.3.1. PD-1/PD-L1 inhibitors
11.3.3.2. CTLA-4 inhibitor
11.3.3.3. Others
11.3.4. Targeted Therapy
11.3.4.1. angiogenesis inhibitors
11.3.4.2. KRAS inhibitor
11.3.4.3. EGFR inhibitors
11.3.4.4. ALK inhibitors
11.3.4.5. Others
11.3.5. Radiation Therapy
11.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacy
11.4.2. Retail Pharmacy
11.4.3. Online Pharmacy
11.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Europe Lung Cancer Market – Opportunity Analysis Index, By Diagnostics Method, By Type, By Treatment, By Distribution Channel and Country, 2022 – 2028
11.7. Europe Lung Cancer Market Dynamics – Trends
12.  Asia-Pacific Lung Cancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
12.1. By Diagnostics Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Chest X-ray
12.1.2. Cytoscopy
12.1.3. 18F-FDG PET scanning
12.1.4. Bronchoscopy
12.1.5. Endobronchial Biopsy Scan (EBUS)
12.1.6. Biopsy
12.2. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Non Non-small Cell lung Cancer
12.2.1.1. Small cell carcinoma (oat cell cancer).
12.2.1.2. Combined small cell carcinoma.
12.2.2. Non-small Cell lung Cancer
12.2.2.1. Squamous cell carcinoma
12.2.2.2. Large cell carcinoma
12.2.2.3. Adenocarcinoma
12.2.2.4. Others
12.3. By Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Surgery
12.3.2. Chemotherapy
12.3.2.1. Platinum Containing Compound
12.3.2.2. Taxanes
12.3.2.3. Antimetabolites
12.3.2.4. vinca alkaloids
12.3.2.5. podophyllotoxin derivatives
12.3.2.6. antifolate antineoplastic agents
12.3.3. Immunotherapy
12.3.3.1. PD-1/PD-L1 inhibitors
12.3.3.2. CTLA-4 inhibitor
12.3.3.3. Others
12.3.4. Targeted Therapy
12.3.4.1. angiogenesis inhibitors
12.3.4.2. KRAS inhibitor
12.3.4.3. EGFR inhibitors
12.3.4.4. ALK inhibitors
12.3.4.5. Others
12.3.5. Radiation Therapy
12.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacy
12.4.2. Retail Pharmacy
12.4.3. Online Pharmacy
12.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Rest of Asia-Pacific
12.6. Asia-Pacific Lung Cancer Market – Opportunity Analysis Index, By By Diagnostics Method, By Type, By Treatment, By Distribution Channel  and Country, 2022 – 2028
12.7. Asia-Pacific Lung Cancer Market Dynamics – Trends
13.  Latin America Lung Cancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
13.1. By Diagnostics Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.1.1. Chest X-ray
13.1.2. Cytoscopy
13.1.3. 18F-FDG PET scanning
13.1.4. Bronchoscopy
13.1.5. Endobronchial Biopsy Scan (EBUS)
13.1.6. Biopsy
13.2. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Non Non-small Cell lung Cancer
13.2.1.1. Small cell carcinoma (oat cell cancer).
13.2.1.2. Combined small cell carcinoma.
13.2.2. Non-small Cell lung Cancer
13.2.2.1. Squamous cell carcinoma
13.2.2.2. Large cell carcinoma
13.2.2.3. Adenocarcinoma
13.2.2.4. Others
13.3. By Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Surgery
13.3.2. Chemotherapy
13.3.2.1. Platinum Containing Compound
13.3.2.2. Taxanes
13.3.2.3. Antimetabolites
13.3.2.4. vinca alkaloids
13.3.2.5. podophyllotoxin derivatives
13.3.2.6. antifolate antineoplastic agents
13.3.3. Immunotherapy
13.3.3.1. PD-1/PD-L1 inhibitors
13.3.3.2. CTLA-4 inhibitor
13.3.3.3. Others
13.3.4. Targeted Therapy
13.3.4.1. angiogenesis inhibitors
13.3.4.2. KRAS inhibitor
13.3.4.3. EGFR inhibitors
13.3.4.4. ALK inhibitors
13.3.4.5. Others
13.3.5. Radiation Therapy
13.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacy
13.4.2. Retail Pharmacy
13.4.3. Online Pharmacy
13.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Argentina
13.5.3. Rest of Latin America
13.6. Latin America Lung Cancer Market – Opportunity Analysis Index, By By Diagnostics Method, By Type, By Treatment, By Distribution Channel and Country, 2022 – 2028
13.7. Latin America Lung Cancer Market Dynamics – Trends
14.  Middle East and Africa Lung Cancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
14.1. By Diagnostics Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.1.1. Chest X-ray
14.1.2. Cytoscopy
14.1.3. 18F-FDG PET scanning
14.1.4. Bronchoscopy
14.1.5. Endobronchial Biopsy Scan (EBUS)
14.1.6. Biopsy
14.2. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Non Non-small Cell lung Cancer
14.2.1.1. Small cell carcinoma (oat cell cancer).
14.2.1.2. Combined small cell carcinoma.
14.2.2. Non-small Cell lung Cancer
14.2.2.1. Squamous cell carcinoma
14.2.2.2. Large cell carcinoma
14.2.2.3. Adenocarcinoma
14.2.2.4. Others
14.3. By Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Surgery
14.3.2. Chemotherapy
14.3.2.1. Platinum Containing Compound
14.3.2.2. Taxanes
14.3.2.3. Antimetabolites
14.3.2.4. vinca alkaloids
14.3.2.5. podophyllotoxin derivatives
14.3.2.6. antifolate antineoplastic agents
14.3.3. Immunotherapy
14.3.3.1. PD-1/PD-L1 inhibitors
14.3.3.2. CTLA-4 inhibitor
14.3.3.3. Others
14.3.4. Targeted Therapy
14.3.4.1. angiogenesis inhibitors
14.3.4.2. KRAS inhibitor
14.3.4.3. EGFR inhibitors
14.3.4.4. ALK inhibitors
14.3.4.5. Others
14.3.5. Radiation Therapy
14.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacy
14.4.2. Retail Pharmacy
14.4.3. Online Pharmacy
14.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Saudi Arabia
14.5.2. GCC Countries
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Lung Cancer Market – Opportunity Analysis Index, By By Diagnostics Method, By Type, By Treatment, By Distribution Channel  and Country, 2022 – 2028
14.7. MEA Lung Cancer Market Dynamics – Trends
15.  Competition Landscape 
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, By Diagnostics Method Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Genentech (F. Hoffmann-La Roche Ltd)
15.2.2. Eli Lilly and Company
15.2.3. Celgene Corporation
15.2.4. AstraZeneca
15.2.5. Pfizer Inc.
15.2.6. Sanofi
15.2.7. Novartis AG
15.2.8. Astellas
15.2.9. Bristol Myers Squibb
15.2.10. Boehringer Ingelheim Pharmaceuticals, Inc.
15.2.11. Millennium Pharmaceuticals, Inc.
15.2.12. Merck Sharp & Dohme Corp.
16.  Research Methodology
17.  Key Assumptions and Acronyms

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX